Underwriters’ over-allotment is a further ~1.67M shares.
Web proceeds might be used for improvement and commercialization of Recorlev in U.S., help the life cycle administration actions of Keveyis and different basic company functions.
Cut-off date is September 21.
Shares down 14% after-hours.
Beforehand: Strongbridge Biopharma readies equity offering (Sept. 16)